(Q53028366)

English

Breaking immune tolerance by targeting CD25+ regulatory T cells is essential for the anti-tumor effect of the CTLA-4 blockade in an HLA-DR transgenic mouse model of prostate cancer.

scientific article published on 11 August 2014

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

10 May 2018

http://europepmc.org/abstract/MED/25111463

Breaking immune tolerance by targeting CD25+ regulatory T cells is essential for the anti-tumor effect of the CTLA-4 blockade in an HLA-DR transgenic mouse model of prostate cancer. (English)

1 reference

Europe PubMed Central

PubMed publication ID

10 May 2018

http://europepmc.org/abstract/MED/25111463

author name string

Elena N Klyushnenkova

1

1 reference

Europe PubMed Central

PubMed publication ID

10 May 2018

http://europepmc.org/abstract/MED/25111463

Vladimir B Riabov

2

1 reference

Europe PubMed Central

PubMed publication ID

10 May 2018

http://europepmc.org/abstract/MED/25111463

Diana V Kouiavskaia

3

1 reference

Europe PubMed Central

PubMed publication ID

10 May 2018

http://europepmc.org/abstract/MED/25111463

Ashley Wietsma

4

1 reference

Europe PubMed Central

PubMed publication ID

10 May 2018

http://europepmc.org/abstract/MED/25111463

Min Zhan

5

1 reference

Europe PubMed Central

PubMed publication ID

10 May 2018

http://europepmc.org/abstract/MED/25111463

Richard B Alexander

6

1 reference

Europe PubMed Central

PubMed publication ID

10 May 2018

http://europepmc.org/abstract/MED/25111463

publication date

11 August 2014

1 reference

Europe PubMed Central

PubMed publication ID

10 May 2018

http://europepmc.org/abstract/MED/25111463

1 reference

Europe PubMed Central

PubMed publication ID

10 May 2018

http://europepmc.org/abstract/MED/25111463

74

1 reference

Europe PubMed Central

PubMed publication ID

10 May 2018

http://europepmc.org/abstract/MED/25111463

14

1 reference

Europe PubMed Central

PubMed publication ID

10 May 2018

http://europepmc.org/abstract/MED/25111463

1423-1432

1 reference

Europe PubMed Central

PubMed publication ID

10 May 2018

http://europepmc.org/abstract/MED/25111463

The blockade of immune checkpoints in cancer immunotherapy

1 reference

https://api.crossref.org/works/10.1002%2FPROS.22858

21 January 2018

Is there a role for immune checkpoint blockade with ipilimumab in prostate cancer?

1 reference

https://api.crossref.org/works/10.1002%2FPROS.22858

21 January 2018

Improved Survival with Ipilimumab in Patients with Metastatic Melanoma

1 reference

https://api.crossref.org/works/10.1002%2FPROS.22858

21 January 2018

Anti-CTLA-4 antibody therapy: immune monitoring during clinical development of a novel immunotherapy

1 reference

https://api.crossref.org/works/10.1002%2FPROS.22858

21 January 2018

Ipilimumab alone or in combination with radiotherapy in metastatic castration-resistant prostate cancer: results from an open-label, multicenter phase I/II study

1 reference

https://api.crossref.org/works/10.1002%2FPROS.22858

21 January 2018

Ipilimumab versus placebo after radiotherapy in patients with metastatic castration-resistant prostate cancer that had progressed after docetaxel chemotherapy (CA184-043): a multicentre, randomised, double-blind, phase 3 trial

1 reference

https://api.crossref.org/works/10.1002%2FPROS.22858

21 January 2018

Synergism of cytotoxic T lymphocyte-associated antigen 4 blockade and depletion of CD25(+) regulatory T cells in antitumor therapy reveals alternative pathways for suppression of autoreactive cytotoxic T lymphocyte responses

1 reference

https://api.crossref.org/works/10.1002%2FPROS.22858

21 January 2018

Basic principles of tumor-associated regulatory T cell biology

1 reference

https://api.crossref.org/works/10.1002%2FPROS.22858

21 January 2018

Increased CD8+ T-cell function following castration and immunization is countered by parallel expansion of regulatory T cells

1 reference

https://api.crossref.org/works/10.1002%2FPROS.22858

21 January 2018

CD4+CD25high T cells are enriched in the tumor and peripheral blood of prostate cancer patients

1 reference

https://api.crossref.org/works/10.1002%2FPROS.22858

21 January 2018

Regulatory T cells: mechanisms of differentiation and function

1 reference

https://api.crossref.org/works/10.1002%2FPROS.22858

21 January 2018

Cell-autonomous and -non-autonomous roles of CTLA-4 in immune regulation

1 reference

https://api.crossref.org/works/10.1002%2FPROS.22858

21 January 2018

Fc-dependent depletion of tumor-infiltrating regulatory T cells co-defines the efficacy of anti-CTLA-4 therapy against melanoma

1 reference

https://api.crossref.org/works/10.1002%2FPROS.22858

21 January 2018

Cutting edge: permissive MHC class II allele changes the pattern of antitumor immune response resulting in failure of tumor rejection

1 reference

https://api.crossref.org/works/10.1002%2FPROS.22858

21 January 2018

A cytomegalovirus-based vaccine expressing a single tumor-specific CD8+ T-cell epitope delays tumor growth in a murine model of prostate cancer

1 reference

https://api.crossref.org/works/10.1002%2FPROS.22858

21 January 2018

Two distinct mechanisms of augmented antitumor activity by modulation of immunostimulatory/inhibitory signals.

1 reference

https://api.crossref.org/works/10.1002%2FPROS.22858

21 January 2018

CTLA-4 blockade in combination with xenogeneic DNA vaccines enhances T-cell responses, tumor immunity and autoimmunity to self antigens in animal and cellular model systems

1 reference

https://api.crossref.org/works/10.1002%2FPROS.22858

21 January 2018

Cancer regression and autoimmunity induced by cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma

1 reference

https://api.crossref.org/works/10.1002%2FPROS.22858

21 January 2018

Regulatory T cells suppress tumor-specific CD8 T cell cytotoxicity through TGF-beta signals in vivo

1 reference

https://api.crossref.org/works/10.1002%2FPROS.22858

21 January 2018

Diversity of antigen-specific responses induced in vivo with CTLA-4 blockade in prostate cancer patients

1 reference

https://api.crossref.org/works/10.1002%2FPROS.22858

21 January 2018

Manipulation of T cell costimulatory and inhibitory signals for immunotherapy of prostate cancer

1 reference

https://api.crossref.org/works/10.1002%2FPROS.22858

21 January 2018

Elimination of residual metastatic prostate cancer after surgery and adjunctive cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) blockade immunotherapy.

1 reference

https://api.crossref.org/works/10.1002%2FPROS.22858

21 January 2018

Potent induction of tumor immunity by combining tumor cryoablation with anti-CTLA-4 therapy

1 reference

https://api.crossref.org/works/10.1002%2FPROS.22858

21 January 2018

Sequencing CTLA-4 blockade with cell-based immunotherapy for prostate cancer

1 reference

https://api.crossref.org/works/10.1002%2FPROS.22858

21 January 2018

Single dose of anti-CTLA-4 enhances CD8+ T-cell memory formation, function, and maintenance

1 reference

https://api.crossref.org/works/10.1002%2FPROS.22858

21 January 2018

Prostate-specific antigen kinetics as a surrogate endpoint in clinical trials of metastatic castration-resistant prostate cancer: a review

1 reference

https://api.crossref.org/works/10.1002%2FPROS.22858

21 January 2018

Current experience with CTLA4-blocking monoclonal antibodies for the treatment of solid tumors

1 reference

https://api.crossref.org/works/10.1002%2FPROS.22858

21 January 2018

Autoimmunity in a phase I trial of a fully human anti-cytotoxic T-lymphocyte antigen-4 monoclonal antibody with multiple melanoma peptides and Montanide ISA 51 for patients with resected stages III and IV melanoma

1 reference

https://api.crossref.org/works/10.1002%2FPROS.22858

21 January 2018

Anti-CCR4 mAb selectively depletes effector-type FoxP3+CD4+ regulatory T cells, evoking antitumor immune responses in humans.

1 reference

https://api.crossref.org/works/10.1002%2FPROS.22858

21 January 2018

Combination of CTL-associated antigen-4 blockade and depletion of CD25 regulatory T cells enhance tumour immunity of dendritic cell-based vaccine in a mouse model of colon cancer

1 reference

https://api.crossref.org/works/10.1002%2FPROS.22858

21 January 2018

Identifiers

10.1002/PROS.22858

1 reference

Europe PubMed Central

PubMed publication ID

10 May 2018

http://europepmc.org/abstract/MED/25111463

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

10 May 2018

http://europepmc.org/abstract/MED/25111463

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q53028366&oldid=1248299781"